Estimating the burden and economic impact of pediatric genetic disease

Main|Search|PHGKB






Last Posted: Dec 20, 2018

---

• Estimating the burden and economic impact of pediatric genetic disease
  N Gonzaludo et al, Genetics in Medicine, December 19, 2018
• Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States.
  Nalysnyk Luba et al. Journal of managed care & specialty pharmacy 2018 Oct 24(10) 1002-1008
• A Proposed Approach for Implementing Genomics-Based Screening Programs for Healthy Adults
  M. Murray and the Genomics and Population Health Action Collaborative, National Academies of Medicine, December 3, 2018
• Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
  Signorovitch James et al. Journal of medical economics 2018 Nov 1-27
• Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
  Yu Tiffany M et al. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2018 Nov 21(11) 1278-1285
• Amplification-free, sequence-specific 16S rRNA detection at 1 aM.
  Koo Bonhye et al. Lab on a chip 2018 07 (15) 2291-2299
• Impact of Precision Medicine on Drug Repositioning and Pricing: A Too Small to Thrive Crisis.
  Tiriveedhi Venkataswarup et al. Journal of personalized medicine 2018 Nov 8(4)
• Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder.
  Groessl Erik J et al. Journal of managed care & specialty pharmacy 2018 Aug 24(8) 726-734
• Impacts for Children Living with Genetic Muscle Disorders and their Parents - Findings from a Population-Based Study.
  Jones Kelly M et al. Journal of neuromuscular diseases 5(3) 341-352
• Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: A cost-effectiveness analysis.
  Gordon Louisa G et al. Prenatal diagnosis 2017 37(12) 1245-1253

more